SCHEMBL2289462

SCHEMBL2289462

Cc1cccc(C)c1Nc1c(-c2ccc(Br)cc2OCC(N)=O)nc2ccc(F)cn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 12/20 0.47
MAPT P10636 8/20 0.47
TP53 P04637 7/20 0.47
POLB P06746 2/20 0.47
TRPA1 O75762 1/20 0.41
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.36
LMNA P02545 2/20 0.35
PRNP P04156 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
KMT2A Q03164 2/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GFER P55789 1/20 0.35
ALOX15 P16050 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289236 0.93 TRPA1 (0.45) GAAMAPTTP53POLBTRPA1
SCHEMBL2290086 0.92 GAA (0.43) GAAMAPTTP53POLBTRPA1
SCHEMBL2292255 0.92 GAA (0.49) GAAMAPTTP53POLBTRPA1
SCHEMBL2293500 0.90 GAA (0.47) GAAMAPTTP53POLBTRPA1
SCHEMBL2287174 0.90 GAA (0.44) GAAMAPTTP53POLBTRPA1
SCHEMBL2290123 0.89 GAA (0.43) GAAMAPTTP53POLBTRPA1
SCHEMBL2287600 0.88 TRPA1 (0.45) GAAMAPTTP53POLBTRPA1
SCHEMBL2287300 0.88 TRPA1 (0.43) GAAMAPTTP53POLBTRPA1
SCHEMBL2291158 0.87 TRPA1 (0.43) GAAMAPTTP53POLBTRPA1
SCHEMBL2294105 0.87 TP53 (0.49) GAAMAPTTP53POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TP53 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.